In an unusual move on Thursday, a federal judge raised the prospect of not approving CVS Health Corp.’s deal to buy insurer Aetna Inc., which closed earlier this week, during a routine portion of the legal process.
Judge Richard Leon of the U.S. District Court for the District of Columbia objected to what he said was the government’s and companies’ treatment of him as a “rubber stamp” for the deal, noting that CVS had closed its deal to buy Aetna for $69 billion on Wednesday.
”It is common for acquisitions to take place before the completion of this final step in the process, and we continue to focus on delivering the potential of the combined company,” CVS said in a statement.
The Ministry of Justice did not immediately request comments.
The Ministry of Justice was completed in October for the merger of the pharmacy and aid company CVS and Aetna, provided that Health Insurance sells the Medicare Part D medication plan to the WellCare Health Plans. The court must ratify the agreement between government and merger companies.
Leon, before starting a trial Monday, expressed the possibility of not making or declining by summer.
“I was examining your movement, not against it. And in the darkness, I had this uneasy feeling when I was kept like a mushroom, ve said Leon, the Justice Department and the lawyers for the two companies, among others, the American Medical Association.
Göre I’m very concerned, I’m concerned that all of you are going on this issue with a rubber stamp, “he said, according to the speech text of the hearing.
Legal warning !
The information, comments and suggestions there are not covered by investment advice. It is based on the author's personal opinions. These views may not fit your financial situation and risk and return preferences. For this reason, based solely on this information, investment decisions may not have the appropriate consequences for your expectation. Our Site is not responsible for any direct or indirect damages incurred by the investors as a result of the use of the information on the Site, deficiencies in the sources, damages incurred by profit, moral damages, or damage to third parties.